HOME >> BIOLOGY >> NEWS
Trial shows which brain cancer patients benefit from temozolomide

Geneva, Switzerland: An international team of scientists and cancer specialists has identified which patients with the deadly form of brain tumours called glioblastomas are likely to live longer if they are treated with temozolomide, and which patients are likely to get only marginal, if any, benefit.

The genetic predictive test on tumour biopsies to identify who will benefit from the drug could be carried out fairly easily in any genetics laboratory and takes only two to three days, although the availability and quality of the tissue is an important issue. If implemented widely it would mean that temozolomide would become a targeted treatment.

Dr. Monika Hegi told the EORTC-NCI-AACR[1] Symposium on Molecular Targets and Cancer Therapeutics in Geneva today (Wednesday 29 September) that the key to predicting which patients will gain from temozolomide was a gene called O-6-methylguanine-DNA methyltransferase (MGMT) which is involved in DNA repair and its respective methylation status in the patient's tumour.

Methylation is one of the ways that cells control which genetic information they will use. If the MGMT promoter is methylated, the MGMT gene is silenced and this means that no MGMT repair enzyme will be produced, thus preventing correction of faults in the DNA.

Dr. Hegi, head of the laboratory of tumour biology and genetics at the Department of Neurosurgery, University Hospital of Lausanne, Switzerland, said that of a total of 573 patients, biopsies from 206 glioblastoma patients had been tested successfully so far in a seven-country trial organised by the EORTC and National Cancer Institute of Canada Clinical Trials Group (NCIC). 45% had a methylated MGMT promoter, meaning that the MGMT gene was silent and their DNA repair system was impaired.

In this tested group 106 of the patients have been treated with radiotherapy and temozolomide. There was a 46% survival rate at two years for the 46 patients in the group who had a
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
41-227-612-205
European Organisation for Research and Treatment of Cancer
29-Sep-2004


Page: 1 2 3

Related biology news :

1. Trial found no impact of Malarone(TM) on performance and alertness tasks
2. Trial drugs for Huntingtons disease inconclusive in slowing disease
3. National Institute on Drug Abuse launches National Drug Addiction Treatment Clinical Trials Network
4. Immunex And Wyeth-Ayerst Laboratories Advance Enbrel Into Phase II/III Clinical Trial For Chronic Heart Failure
5. Gene Therapy Trial Approved For Rare Anemia
6. Severe Pain Following Shingles Safely Relieved In Clinical Trial Of Anti-Convulsant Drug Gabapentin
7. Cardiac Clinical Trial Studies Use of Antibiotic In Preventing Heart Attack
8. Clinical Trials Show That Bone Marrow Transplant And Vitamin A Derivative Both Improve Survival From Neuroblastoma
9. Novel Drug Trial To Treat Advanced Prostate Cancer Enrolling Patients At UCSF/Mount Zion Cancer Center
10. Targeted Genetics, M.D. Anderson Cancer Center And University Of Pittsburgh Report Phase I Clinical Trial Results Of Gene Therapy Treatment For Cancer
11. Experimental Trial Combines DNA Vaccine With Triple-Drug Therapy To Stop HIV

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/29/2018)... ... August 28, 2018 , ... Johanna Dwyer, founder ... recognizes women of excellence in the field of intellectual property, and named Daniela ... Women in IP Award aims to encourage and support women in their pursuit ...
(Date:8/26/2018)... ... August 25, 2018 , ... ... impact of a biofield energy treated nutraceutical to reduce inflammation and autoimmune disorders ... function and blood, as well as inflammation. The following data was reported:, ...
(Date:8/21/2018)... ... August 20, 2018 , ... When ... challenges to consider. Designers must ensure what is designed can be manufactured reliably ... some best practices in flow path design with specific focus on layered manifold ...
Breaking Biology News(10 mins):
(Date:8/23/2018)... (PRWEB) , ... August 23, 2018 , ... Visikol ... Visikol Co-Founder Dr. Thomas Villani. Through support from advisors, mentors, the Rutgers Technology Transfer ... , Visikol’s path from an idea to a successful biotech company has been ...
(Date:8/17/2018)... ... ... The opening of the new Titusville facility marks the completion of the process ... well established local presence, servicing the Space Coast since 1972. Astro Pak continues that ... at the Mobile Launch Platform (MLP) in support of NASA’s upcoming Space Launch System ...
(Date:8/17/2018)... ... August 17, 2018 , ... VANCOUVER, British Columbia, Canada, ... is pleased to announce the release of the Russian translation of Best Practices: ... January 2018, is a practice-changing publication aimed at advancing the science of biobanking ...
(Date:8/14/2018)... England (PRWEB) , ... August 14, 2018 , ... ... received further impetus at the 11th Congress of the Chinese Association of Orthopaedic ... this event, Fule Science & Technology Development , Beijing, and Invibio ...
Breaking Biology Technology:
Cached News: